And there are investors who are ready to deploy money into the sector. I think the biotechs will be the place to be. And in the fall, when investors start hearing more about the human-genome conferences, you'll see even more interest in the sector. Additionally, I think we'll see more mergers in the biotech space. The sector has matured.
Management is more experienced and smarter.
These companies are flush with cash and they're completely different animals than they were ten years ago. At time of publication Eneida Guzman did not own or control any of the securities mentioned in this column. All rights reserved.